Brief: Universal Biosensors Entered Agreement For Commercialisation Of A Sars-Cov-2 N-Protein Detection Test
24/12/2021 01:33
Dec 24 (Reuters) - Universal Biosensors Inc UBI.AX :
* ENTERED GLOBAL EXCLUSIVE LICENSE AGREEMENT WITH IQ SCIENCE
FOR
COMMERCIALISATION OF A SARS-COV-2 N-PROTEIN DETECTION TEST
Source text for Eikon: urn:newsml:reuters.com:*:nASX9jFYFz
Further company coverage: UBI.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Universal Biosensors
See all newsBrief: Universal Biosensors Seeks Trading Halt Pending Announcement On Financial Position & Funding
Brief: Universal Biosensors Signs Non-Binding Term Sheet For A$8.5M Funding
Brief: Universal Biosensors Seeks Trading Halt
Brief: Universal Biosensors Inc Posts Qtrly Total Revenue A$1.6 Million
Brief: Universal Biosensors Says John Sharman Steps Down As Managing Director And CEO